- Home
- TRVI vs PFL Comparison
TRVI vs PFL Comparison
Compare TRVI & PFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRVI | PFL |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 362.1M |
| IPO Year | 2019 | 2003 |
Fundamental Metrics
Financial Performance| Metric | TRVI | PFL |
|---|---|---|
| Price | $10.37 | $7.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $21.55 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 224.2K |
| Earning Date | 03-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.53% |
| EPS Growth | ★ 31.91 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.85 | $7.11 |
| 52 Week High | $14.39 | $8.70 |
Technical Indicators
Market Signals| Indicator | TRVI | PFL |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 24.57 |
| Support Level | $10.04 | N/A |
| Resistance Level | $11.78 | $8.49 |
| Average True Range (ATR) | 0.74 | 0.09 |
| MACD | -0.20 | -0.04 |
| Stochastic Oscillator | 1.26 | 1.52 |
Price Performance
Historical ComparisonAbout TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. The company seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.